We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The to-be-reported quarter’s earnings results are likely to reflect high revenues. The Zacks Consensus Estimate for third-quarter earnings stands at $4.61, indicating an upside of 49.7% from the prior-year quarter's reported figure.
For the third quarter, management expects a low 20s percentage of its full year 2021 guidance per the last earnings call. The consensus mark for revenues stands at $20.8 billion, implying an upside of 4% from the year-ago quarter’s reported number.
The company’s top line is likely to have witnessed an upside in the third quarter owing to higher premiums and strong Medicaid and Medicare lines of businesses. It is also likely to have gained from state-based membership growth, and a solid contribution from its Retail and Healthcare Services segments.
The consensus mark for total medical membership and total premiums suggests a hike of 1.2% and 5.4% each from the respective year-ago quarter’s reported figures.
However, specialty membership might have partially taken a hit from membership migration. The consensus mark for the same is almost in line with the prior-year quarter’s reported figure.
The company is expected to have witnessed an uptick in its telehealth services owing to current demand for the same.
Total investment income for the to-be-reported quarter is expected to have noticed a downtrend due to low investment yield.
What the Quantitative Model States
Our proven model doesn’t predict an earnings beat for Humana this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates, which is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Humana currently carries a Zacks Rank #4 (Sell).
Highlights of Q2 Earnings and Surprise History
Humana’s second-quarter 2021 operating earnings per share of $6.89 surpassed the Zacks Consensus Estimate by 0.4%. This was on the back of better revenues and a solid contribution from its Retail and Healthcare Services segments. The bottom line, however, declined 45.1% year over year.
The company boasts a stellar earnings record with its bottom line having delivered a positive surprise in all the trailing four quarters, the average being 4.16%
Stocks to Consider
Here are a few stocks worth considering from the medical sector with the perfect mix of elements to beat on earnings this reporting cycle:
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +0.87% and is presently Zacks #3 Ranked.
Canopy Growth Corporation (CGC - Free Report) is currently #3 Ranked and has an Earnings ESP of +26.83%.
Zoetis Inc. (ZTS - Free Report) has an Earnings ESP of +5.45% and a Zacks Rank of 3 at present.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
Humana Inc.’s (HUM - Free Report) third-quarter 2021 earnings results are scheduled to be reported on Nov 3, 2021.
Factors to Impact Q3 Results
The to-be-reported quarter’s earnings results are likely to reflect high revenues. The Zacks Consensus Estimate for third-quarter earnings stands at $4.61, indicating an upside of 49.7% from the prior-year quarter's reported figure.
For the third quarter, management expects a low 20s percentage of its full year 2021 guidance per the last earnings call. The consensus mark for revenues stands at $20.8 billion, implying an upside of 4% from the year-ago quarter’s reported number.
The company’s top line is likely to have witnessed an upside in the third quarter owing to higher premiums and strong Medicaid and Medicare lines of businesses. It is also likely to have gained from state-based membership growth, and a solid contribution from its Retail and Healthcare Services segments.
The consensus mark for total medical membership and total premiums suggests a hike of 1.2% and 5.4% each from the respective year-ago quarter’s reported figures.
However, specialty membership might have partially taken a hit from membership migration. The consensus mark for the same is almost in line with the prior-year quarter’s reported figure.
The company is expected to have witnessed an uptick in its telehealth services owing to current demand for the same.
Total investment income for the to-be-reported quarter is expected to have noticed a downtrend due to low investment yield.
What the Quantitative Model States
Our proven model doesn’t predict an earnings beat for Humana this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates, which is not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Humana has an Earnings ESP of +0.08%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Humana Inc. Price and EPS Surprise
Humana Inc. price-eps-surprise | Humana Inc. Quote
Zacks Rank: Humana currently carries a Zacks Rank #4 (Sell).
Highlights of Q2 Earnings and Surprise History
Humana’s second-quarter 2021 operating earnings per share of $6.89 surpassed the Zacks Consensus Estimate by 0.4%. This was on the back of better revenues and a solid contribution from its Retail and Healthcare Services segments. The bottom line, however, declined 45.1% year over year.
The company boasts a stellar earnings record with its bottom line having delivered a positive surprise in all the trailing four quarters, the average being 4.16%
Stocks to Consider
Here are a few stocks worth considering from the medical sector with the perfect mix of elements to beat on earnings this reporting cycle:
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +0.87% and is presently Zacks #3 Ranked.
Canopy Growth Corporation (CGC - Free Report) is currently #3 Ranked and has an Earnings ESP of +26.83%.
Zoetis Inc. (ZTS - Free Report) has an Earnings ESP of +5.45% and a Zacks Rank of 3 at present.